Proud to share our experience from the @SanRaffaeleMI #VHL Program assessing PROMs in VHL 🔑VHL patients show more depression than those with sporadic RCC 🧠Psychological support must be part of SoC for hereditary cancer syndromes! @VHLAlliance @JCOOA_ASCO https://t.co/NWkxD3m8jk

💡Assessing #pathological response to #neoadjuvant therapy in #renal cell carcinoma: a systematic review and #guidelines for sampling and reporting standards from the International Neoadjuvant Kidney Cancer Consortium https://t.co/LVZqT4Meea @TheLancetOncol It is a true honor

🌍📈🧬 #Epidemiology of #RenalCancer: #Incidence, #Mortality, #Survival, #GeneticPredisposition, and #RiskFactors https://t.co/YKFXuvZzP9 Up-to -date facts and figures together with future projections at @EUplatinum

📢 Don’t miss the next @Urowebinar on innovations in localized RCC! 🧬 Biomarkers, 🎯 SBRT, 🧠 molecular imaging – the future of RCC care. 🗓️ Tue, 19 Aug 2025 | 🕒 18:30 CEST 🔗 Pre-register now: https://t.co/KDbGQDWTIN @Uroweb @UrowebESU

Heading back home after a few intense days at @orsiacademy to achieve the product training certification for the Hugo robotic system. Skills, technology and teamwork combined to create a unique training experience. Great time with the @Medtronic team! #SurgicalInnovation #Urology

📘 Just published in European Urology: 🔄 The 2025 EAU Guidelines on UTUC are here! 🧬 Major updates include: • Revised risk stratification framework • New recommendations for kidney-sparing approaches in low-risk UTUC • Clarified indications for perioperative chemotherapy &

In papillary kidney cancer, particularly hereditary leiomyomatosis–associated cases, bevacizumab plus erlotinib showed strong antitumor activity. The likelihood of a response was higher in hereditary cases than in sporadic ones. Full study results: https://t.co/wuTUmtq1XN

Just wrapped up an amazing #AUA2025 in Las Vegas! Cutting-edge urology research, inspiring talks, and great networking made it unforgettable. Huge thanks to the incredible HSR team for sharing the journey! #urology #AUAAnnualMeeting @MyUniSR @SanRaffaeleMI

Only 4 days to go! Really looking forward to the #AUA25 @AmerUrological in Las Vegas! @SanRaffaeleMI @MyUniSR

#EAU25 Congress in Madrid is already one week away! Amazing chance to present our projects, share ideas, learn from the brightest opinion leaders and celebrate the #WillyGregoir award received by our exceptional mentor @F_Montorsi. Ready for the next!🇺🇸 @SanRaffaeleMI @MyUniSR

Fantastic to see Raghav Varma presenting at the National Ipsen RCC day on the important National Kidney Cancer Audit by @grantissimus et al on variations in kidney cancer care across the UK. Much work to do! @CRUKCamUrol @CUH_NHS @kidneycanceruk @CRUKCamCentre

🎉Great to see out a massive team work led by @dr_h_harrison and @grantissimus In most cancers there is no evidence that intensive, long-term radiological surveillance after curative surgery improves survival or QoL. @srossi725 @JulietU_S @lambwben @HPBCambridge @CRUKCamUrol

https://t.co/PLqSYUHe9B In @EUplatinum during @kidneycan #KCRS24. Thank you Axel and Grant for leading the charge !

Truly honoured to have joined the first edition of the Florence Multidisciplinary Expert Meeting on RCC. Two inspiring days of lectures, debates, and new collaborations with the top European minds in the field. @Flo_exp_RCC_25 @Ric_Campi @u_capitanio @_alelarcher @grantissimus

IT IS THIS TIME OF THE YEAR AGAIN! TOP 10 GU Bladder/Kidney Cancer TRIALS FOR 2024 1/ Enfortumab Vedotin (EV) + Pembrolizumab new SOC for patients with metastatic #UC. Trial #EV302 displaced 30y Platinum-based combos ⏩ PFS benefit: 12.5 vs 6.3 mo (HR= 0.45) ⏩ OS benefit:

Here we go: News from Europe and the @EMA_News: the first HIF2 inhibitor Belzutifan (already @US_FDA) receives POSITIVE opinion for renal cancer in 1) VHL patients, 2) refractory RCC--Both studies published @NEJM with 1) led by @EJonasch, 2) presented by @AlbigesL @myESMO #ESMO23

🎉EXCITING NEWS 👇 @CRUKCamUrol researchers, led by @grantissimus and @JulietU_S, have published the world’s first prospective study of screening for #kidneycancer: the Yorkshire Kidney Screening Trial (YKST). 📖Available to read now in @EUplatinum

Extremely true!

Just in @NEJM 👉the primary results of ph3 @SWOG 1011 trial (n=592)👉in pts with muscle-invasive #bladdercancer undergoing radical cystectomy👉standard lymphadenectomy is sufficient (extended lymphadenectomy did not improve survival outcomes)👇Link: https://t.co/qqrugSnXpn

Save the date🚨 Oct 18-20 @SanRaffaeleMI and @MyUniSR host the leading global experts in Von Hippel-Lindau disease and #renalcancer